1. Home
  2. COHN vs SYBX Comparison

COHN vs SYBX Comparison

Compare COHN & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COHN
  • SYBX
  • Stock Information
  • Founded
  • COHN 1999
  • SYBX N/A
  • Country
  • COHN United States
  • SYBX United States
  • Employees
  • COHN N/A
  • SYBX N/A
  • Industry
  • COHN Investment Bankers/Brokers/Service
  • SYBX Biotechnology: Pharmaceutical Preparations
  • Sector
  • COHN Finance
  • SYBX Health Care
  • Exchange
  • COHN Nasdaq
  • SYBX Nasdaq
  • Market Cap
  • COHN 20.2M
  • SYBX 17.0M
  • IPO Year
  • COHN N/A
  • SYBX N/A
  • Fundamental
  • Price
  • COHN $10.18
  • SYBX $1.50
  • Analyst Decision
  • COHN
  • SYBX Hold
  • Analyst Count
  • COHN 0
  • SYBX 3
  • Target Price
  • COHN N/A
  • SYBX $1.00
  • AVG Volume (30 Days)
  • COHN 6.5K
  • SYBX 81.9K
  • Earning Date
  • COHN 03-05-2025
  • SYBX 11-12-2024
  • Dividend Yield
  • COHN 9.73%
  • SYBX N/A
  • EPS Growth
  • COHN N/A
  • SYBX N/A
  • EPS
  • COHN 2.35
  • SYBX N/A
  • Revenue
  • COHN $89,555,000.00
  • SYBX $2,777,000.00
  • Revenue This Year
  • COHN N/A
  • SYBX N/A
  • Revenue Next Year
  • COHN N/A
  • SYBX N/A
  • P/E Ratio
  • COHN $4.38
  • SYBX N/A
  • Revenue Growth
  • COHN 63.18
  • SYBX 292.23
  • 52 Week Low
  • COHN $6.10
  • SYBX $1.22
  • 52 Week High
  • COHN $12.82
  • SYBX $3.96
  • Technical
  • Relative Strength Index (RSI)
  • COHN 46.83
  • SYBX 59.28
  • Support Level
  • COHN $10.13
  • SYBX $1.36
  • Resistance Level
  • COHN $10.65
  • SYBX $1.52
  • Average True Range (ATR)
  • COHN 0.44
  • SYBX 0.08
  • MACD
  • COHN -0.07
  • SYBX 0.01
  • Stochastic Oscillator
  • COHN 45.83
  • SYBX 59.70

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Share on Social Networks: